A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed as a phase 1, multicenter, open-label, single arm, dose-escalation, study of Cabazitaxel in combination with cisplatin, to determine safety, pharmacokinetics (PK), and efficacy in solid tumors (parts 1 and 2) and single sequence, two-treatment, crossover studies to determine the effect of strong CYP3A4 inhibition and induction on the PK of Cabazitaxel in patients with solid tumors (part 3 and part 4, respectively).

There are 4 parts to the study:

Part 1: Determine the Dose Limiting Toxicities (DLT)'s and Maximum Tolerated Dose (MTD) based on safety.

Part 2: Determine the anti-tumor activity of the combination regimen at the Maximum Tolerated Dose (MTD) in an extended cohort of patients.

Part 3: Determine the effect of a strong CYP3A4 inhibitor (ketoconazole) on the pharmacokinetic (PK) of Cabazitaxel.

Part 4: Determine the effect of a strong CYP3A4 inducer (rifampin) on the pharmacokinetic (PK) of Cabazitaxel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

NCT01140607

Neoplasm Malignant

COMPLETED PHASE1

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

NCT01001221

Neoplasms, Malignant

TERMINATED PHASE1/PHASE2

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

NCT01755390

Advanced Solid Tumor

COMPLETED PHASE1

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

NCT00136578

Solid Tumours

COMPLETED PHASE1

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

NCT00086528

Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The total duration on the study per subject will be about 26 weeks broken down as follows:

* A maximum of 21-day screening phase,
* 21-days (+/- 2 weeks) study treatment cycles,
* 30-day follow-up visit after the last dose of study medication.
* Cut-off date for parts 1, 2, 3 and 4: when the last patient has completed 6 cycles (parts 1 and 2) or 2 cycles (parts 3 and 4) of treatment or discontinued study treatment (for disease progression, unacceptable toxicity, withdrawal of consent, or investigator's decision to withdraw), whichever comes first, in the corresponding part.

Patients still receiving treatment at the cut-off date may continue to receive treatment beyond the cut-off date at investigator's discretion if benefiting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

* 5, 15, 20 or 25 mg/m2
* one injection of cabazitaxel on day 1 of each cycle (3 weeks)

Group Type EXPERIMENTAL

cabazitaxel (XRP6258)

Intervention Type DRUG

* administered by IV infusion
* in addition to cisplatin treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cabazitaxel (XRP6258)

* administered by IV infusion
* in addition to cisplatin treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed metastatic or unremovable advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist, but for which cisplatin based therapy is appropriate
* signed informed consent

Exclusion Criteria

* limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale)
* inability to follow study requirements and schedule
* treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other cancer therapy
* serious medical illness at same time of study and/or significantly abnormal lab reports
* lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding.
* Women of childbearing potential not protected by highly effective contraceptive method of birth control OTHER than hormonal contraception (Part 4 only).
* prior significant hearing or kidney problems
* continued toxic effects of prior chemotherapy
* cancers that cannot be physically measured (Part 2 only)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No